Status:

COMPLETED

Safety Study of Atomoxetine and Cerebrovascular Outcomes

Lead Sponsor:

Eli Lilly and Company

Collaborating Sponsors:

i3 Drug Safety

Conditions:

Cerebrovascular Accident

Transient Ischemic Attack

Eligibility:

All Genders

18+ years

Brief Summary

Using a proprietary insurance health claims database, Eli Lilly and Company has contracted with an external party to conduct a retrospective cohort study of health claims for the time period from 1 Ja...

Eligibility Criteria

Inclusion

  • patients 18 years or older
  • received dispensing of one of the study medications during the time period of the study (January 1, 2003 - December 31, 2006)
  • 6 months of continuous enrollment prior to first dispensing

Exclusion

  • presence of pre-existing arrhythmia and heart failure during the baseline period

Key Trial Info

Start Date :

January 1 2008

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

September 1 2008

Estimated Enrollment :

72000 Patients enrolled

Trial Details

Trial ID

NCT00634439

Start Date

January 1 2008

End Date

September 1 2008

Last Update

September 15 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician

Indianapolis, Indiana, United States

Safety Study of Atomoxetine and Cerebrovascular Outcomes | DecenTrialz